Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Healthcare >

Theralase Technologies Inc. (TLTFF)

Add TLTFF Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 8/21/2017 4:58:29 PM - Followers: 71 - Board type: Free - Posts Today: 1


Jan 22, 2014 7:20 AM | about stocks: TLTFF


Theralase Technologies Inc. (TSX-V: TLT, US-OTCBB: TLTFF). They design, develop, manufacture and market, patented, super-pulsed laser technology used in biostimulative and biodestructive clinical applications. The Theralase technology platform targets several health-care sectors: First, for non-invasive pain management and clinical therapy, used in neural muscular skeletal conditions, including arthritis and osteoarthritis; Second, wound care and healing (including non-healing fractures and bone fracture regeneration); And third, research and development into combining patented photodynamic compounds (PDCs) with patented, super-pulsed, biofeedback laser technology to attack specifically targeted cancers, bacteria and viruses.

The company is currently focused on the commercialization (production, marketing and distribution) of the TLC-2000 Superpulsed Laser Technology to healthcare practitioners, and commercialization of the patented TLC-3000 Photo Dynamic Compound Cancer Technology through pre-clinical research and clinical trials.

Key Investment Highlights:

  • Working on breakthrough bladder cancer destruction technology and has achieved tremendous success in pre-clinical trials
    Proven clinical technology (TLC-1000) and commercial therapeutic laser business and brand developed over last 17 years, currently generating ~2M of revenue annually
    Rollout of new TLC-2000 technology in 2014, along with a new recurring revenue business model
    Strategic agreements in place with world renowned institutions to help advance research and mitigate expenses
    Competitive technical advantages (Cellular pathways: iNOS, ATP, Na+ / K+)
    Future technology (patented biofeedback technology and patented PDC cancer destruction)
    IP protection (multiple issued patents)
    Large addressable US markets ($ billions)
    No debt
    Positive cash flow / double digit growth
    Lots of opportunity for short-term and long-term growth (revenue & profit)
    Experienced management team (20+ years)
    Clear vision and execution strategy


Theralase has patented anti-cancer drugs known as Photo Dynamic Compounds (PDCs) which localize the DNA of cancer cells and when irradiated, destroy the DNA resulting in apoptosis (natural cell death). While PDCs are used in Photodynamic Therapy (PDT) as a potential treatment regime for a number of conditions, Theralase has discovered that they hold particular promise as treatment to particular cancers. Theralase PDCs have proven successful in destroying breast, colon, brain and bladder cancer cells. Recent lab results have shown that Theralase was able to completely destroy subcutaneous bladder cancer tumors in mouse models. "The achievement of this important milestone signifies that Theralase's leading drug candidate is effective in the destruction of cancer in a live animal model and can prevent the cancer from recurring," commented Roger White of Theralase.

Key Market Statistics:

  • US bladder cancer treatment annual spending was $3.9 billion in 2012
    70,000 new cases, > 14,000 deaths in the US each year
    386,000 new cases are diagnosed worldwide annually
    Standard treatment unchanged with no new drugs approved since 1998
    5th most common cancer, 4th in men, 8th in women
    Most expensive cancer to treat with a recurrence rate up to 80%
    70% of new bladder cancer cases are early stage disease and 90% of bladder cancers are Transitional Cell Carcinoma (TCC)

Theralase PDC Characteristics:

  • Up to 100% cancer cell kill at very low concentrations (< 0.8μM)

(click to enlarge)

  • More effective at killing cancer cells than FDA approved drugs

(668,000x ALA, 198x PHOTOFRIN)

  • Survival of mice up to 20 months (50 human years) after one Theralase PDT treatment

(click to enlarge)

We are VERY IMPRESSED, and VERY EXCITED about these results! In 2012, annual spending for bladder cancer treatment in the US was $3.9 billion, and the current standard of care has been unchanged with no new drugs approved since 1998. Bladder cancer is the most expensive cancer to treat, and has a recurrence rate up to 80%. All of the mice which showed an initial response have remained cancer free, healed without scarring, and have developed normally after only one Theralase PDC treatment. Needless to say, the early results from Theralase look extremely positive. Imagine being able to not only provide treatment for bladder cancer, but to actually cure it, and stop it from coming back! The company is also working on developing further PDCs that can be used to treat a wide variety of other cancers (breast, colon, brain and lung), as well as bacteria and viruses.

  • The general patent protects 1,000s of molecules - essentially a library of PDCs
    Virtually 0% toxicity at high concentrations (> 100μM) leading to ultra-high safety profile
    Activated by laser light providing excellent specificity and selectivity
    Able to treat solid core hypoxic tumors, such as: breast, prostate and lung
    Research outsourced to and performed at world renowned Princess Margaret Cancer Centre
    Patented under numerous US and International Patents:
    Issued USA Patents: 6,962,910, 7,612,057, 8,148,360, 8,445,475
    Pending USA Patent Applications: 61/801,674, 13/863,089, 13/36595

To help explain how the procedure works we sketched a diagram:

(click to enlarge)

  1. A catheter is inserted into the patient
    The PDC is injected and saturates within the patient's bladder, penetrating the cellular membrane (DNA localizing)
    Fiber optics cables are inserted up the catheter into the bladder
    Using laser technology, light is irradiated 360°
    The entire procedure takes about 2 - 3 hours

Theralase is currently completing the validation of the orthotopic rat model, a dose toxicity study, GMP drug manufacture, and FDA Investigational New Drug (IND) application. The next phase is to complete an FDA phase 1/2a human clinical study with FDA breakthrough status, and then to execute a strategic partnership agreement with big pharmaceutical (pharma) company (upfront payments, co-development funds, annual recurring revenue streams).

Industry comparables:

(click to enlarge)

(click to enlarge)

Deals with comparable big pharma companies have yielded anywhere from $466M to $1B plus royalties.


The thing is, by the time clinical trials have been completed (assuming they're successful), Theralase will be trading many multiples higher than today. Look how excited investors got when Theralase first released PDC breast cancer results during January 2010, the intraday high for TLT was $1.39/share:

Read More :

Themes: Biotechnology, Micro Capitalization, Growth Opportunity, Pharmaceuticals, Cancer, Laser Technology, Photo Dynamic Compounds (PDCs) Stocks: TLTFF
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TLTFF News: Theralase Demonstrates 18 Month Stability of Lead Anti-Cancer Drug 03/15/2017 07:02:00 AM
TLTFF News: Theralase Anti-Cancer Technology Picks Up Steam 01/06/2015 07:00:00 AM
TLTFF News: Theralase CEO to Be Interviewed Today on Clear Channel Business Talk Radio DFW 1190AM 03/12/2014 07:05:00 AM
TLTFF News: Theralase Achieves Commercialization Milestone For Its Bladder Cancer Therapy 03/14/2013 07:00:04 AM
#2999   hmmm....notable price and volume surge at end of citoyen 08/21/17 04:58:29 PM
#2998   big pharma AND big healthcare companies have to heavymetal 08/14/17 11:04:18 AM
#2997   Jason, Mexus is my biggest holding, I wouldn't Gene_Simmons 08/14/17 03:18:57 AM
#2996   Hey Gene, thanks for the info! Keeping this Jason_Bourne 08/14/17 12:02:48 AM
#2995   what is "fast track"? heavymetal 08/13/17 09:36:07 AM
#2994   jason....gene has answered your questions well, so i citoyen 08/11/17 12:25:21 PM
#2993   I'm sure I'm the last one to notice SurgGuy 08/11/17 09:09:30 AM
#2992   Jason, hope this is at least a little Gene_Simmons 08/11/17 07:08:27 AM
#2991   Hey bud, good to see you here too! Jason_Bourne 08/10/17 05:35:02 PM
#2990   Jason... can't advise re MXSG or TLTFF purchase. citoyen 08/09/17 02:59:42 PM
#2989   Hey buddy! Saw you post the other day Jason_Bourne 08/09/17 02:25:04 PM
#2988   Man, if I only knew. We are blessed Gene_Simmons 08/09/17 01:42:25 PM
#2987   Gene and all... citoyen 08/09/17 01:21:37 PM
#2986   The GBM with osmium is should be next Again MIKE22CA 08/09/17 11:29:00 AM
#2985   I think you might be right on that. Gene_Simmons 08/09/17 10:32:26 AM
#2984   The warrants are feeding the kitty. The next MIKE22CA 08/09/17 10:25:50 AM
#2983   Last PP we didn't have anything. Now we Gene_Simmons 08/09/17 09:53:09 AM
#2982   Exactly. CUIN2 08/08/17 08:49:04 PM
#2981   They are up for another round of financing MasterSalix 08/08/17 05:21:53 PM
#2980   What will it take to get this stock abun 08/08/17 02:53:31 PM
#2979   That PR was released on Accesswire but I Anesthesia 2007 08/08/17 01:48:14 PM
#2978   Still anemic volume when a PR like todays, CUIN2 08/08/17 01:11:38 PM
#2977   Gotta love the positive attention this stock has SurgGuy 08/08/17 12:01:57 PM
#2976   every time i buy a chunk of this heavymetal 08/08/17 09:19:58 AM
#2975   Back YahooFINANCE Share Theralase Anti-Cancer Technology Effective for the Destr CUIN2 08/08/17 07:49:29 AM
#2974   ok, I thought there has been an official suerte88 08/08/17 06:29:31 AM
#2973   my point is, the fact that the stock heavymetal 08/08/17 06:19:11 AM
#2972   Where do you see that? suerte88 08/08/17 05:53:19 AM
#2971   Let it grow to a billion dollar market Gene_Simmons 08/08/17 05:05:01 AM
#2970   theralase is already for sale to the highest heavymetal 08/08/17 04:50:26 AM
#2969   Bcg side effects Table 1 itsallgood11 08/02/17 10:31:51 PM
#2968   we do not have to put our company heavymetal 08/02/17 10:02:23 AM
#2967   in my opinion theralase's method of of treating heavymetal 08/02/17 09:35:18 AM
#2966   I appreciate your feedback CUIN and I agree SurgGuy 08/01/17 08:01:35 AM
#2965   Not according to this PR. 4th done CUIN2 08/01/17 07:52:59 AM
#2964   Does this mean that they have all 6 SurgGuy 08/01/17 07:46:08 AM
#2963   Theralase PDT Technology Used to Treat Fourth Patient itsallgood11 08/01/17 07:23:45 AM
#2962   News. Nice. itsallgood11 08/01/17 07:08:13 AM
#2961   i see phase 1b as an opportunity to heavymetal 07/31/17 06:29:26 AM
#2960   :-) Here's to a new 52w high next week! Gene_Simmons 07/30/17 02:58:56 PM
#2959   I will do as you asked. Gene_Simmons 07/30/17 12:57:02 PM
#2957   I think nasdaq is a real possibility in MIKE22CA 07/30/17 11:38:24 AM
#2956   Yes, that latest PR was legendary. Hope it Gene_Simmons 07/30/17 11:27:53 AM
#2955   You couldnt of asked for a better dsab MIKE22CA 07/30/17 10:05:47 AM
#2954   I wonder if Roger is back from his Gene_Simmons 07/30/17 08:45:48 AM
#2953   Coming up on new 52-week high on good citoyen 07/28/17 02:33:34 PM
#2952   TLTFF has a reported store ($1.6M) of cash 123414 07/27/17 06:12:07 AM
#2951   article- 123414 07/27/17 06:07:14 AM
#2950   It is so clear that this stock will abun 07/26/17 09:27:00 AM
#2949   the second stage of this rocket should move heavymetal 07/26/17 07:04:26 AM